Abstract #0618

In vivo MRI detection of β-amyloid pathologies at early and late stages of Alzheimer’s disease

Celia M. Dong^1,2, Anthea To^1,2, Shuai Guo^1,2, Kannie W. Y. Chan^3,4,5, Alex T. L. Leong^1,2, and Ed X. Wu^1,2

¹Laboratory of Biomedical Imaging and Signal Processing, The University of Hong Kong, Hong Kong, China, ²Department of Electrical and Electronic Engineering, The University of Hong Kong, Hong Kong, China, ³Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, China, ⁴F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Research Institute, Baltimore, MD, United States, ⁵Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States

Early diagnosis of Alzheimer’s disease (AD) is crucial. However, there is a lack of effective diagnostic tools to detect AD at the early stage. Early stage β-amyloid (Aβ) oligomers (AβOs) and late stage Aβ plaques are the pathological hallmarks of AD brains. Recently, we have synthesized a novel curcumin-conjugated magnetic nanoparticle (Cur-MNP) to target Aβ pathologies, visualized in MRI. In this study, we investigated the in vivo feasibility of Cur-MNPs to detect the Aβ pathologies at early and late stages of AD progression, and performed immunohistology to validate the specific targeting of Aβ pathologies.

This abstract and the presentation materials are available to members only; a login is required.

Join Here